Latest News
Regeneron Pharmaceuticals, Inc.
- Regeneron and Sanofi expand antibody alliance in potential $8 billion deal
- Regeneron, Sanofi Expand Alliance with $1 Billion Upfront, 4 Antibodies
- Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial
- Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs
- A New Chapter for the Regeneron-Sanofi Alliance:
- Sanofi and Regeneron expand immunology partnership to the tune of $8bn
- Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal
- Regeneron, Sanofi expand alliance with $1 billion upfront deal
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
- Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
- Big Pharma's Big Brand: Regeneron's science-driven communications approach
- Why is Regeneron Pharmaceuticals stock down 3.4% today?
Headlines from the last 30 days, linking to the original publishers. See all market news →